Here are the 10-Q quarterly reports from BlossomHill Therapeutics, Inc. (BLSM) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BLSM and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BLSM filings page.
BlossomHill Therapeutics, Inc. (BLSM), a clinical-stage oncology company, reported higher operating losses for the quarter ended June 30, 2026 as it expanded development of its three lead small-molecule programs BH-30643 (EGFR NSCLC), BH-30236 (CLK inhibitor for myeloid malignancies) and BH-501284 (pan‑KRAS).
For the quarter, the company generated no product revenue and recorded a net loss of $23.8 million, up from $13.2 million a year earlier; the six‑month net loss was $44.8 million, driven by a doubling of research and development spending to $41.3 million. Cash and cash equivalents were $95.4 million at June 30, 2026, before the August IPO that brought in $151.7 million of net proceeds. Management states that existing cash plus IPO proceeds are expected to fund operations into the second quarter of 2028, while clinical plans advance, including an FDA Fast Track–designated path and a planned pivotal Phase 2 trial for BH-30643 in EGFR C797S‑positive NSCLC and IND‑enabling work for BH‑501284.